Aug 2026· Neurology, neuropsychiatry, Psychosomatics· Vol 18, pp. 98-102· 0 citations· 24 references
TL;DR
A 40-year-old female patient with encephalomyelitis associated with antibodies to GFAP presented with the onset of numbness and weakness in the lower limbs, accompanied by pelvic organ dysfunction, leading to a diagnosis of autoimmune anti-GFAP astrocytopathy.
Abstract
Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP) is a rare condition associated with the presence of antibodies against an intermediate protein located between the finer microfilaments and the larger microtubules in astrocytes. The condition remains poorly understood, necessitating further research to improve diagnosis and treatment. This article presents a clinical case of encephalomyelitis associated with antibodies to GFAP. In a 40-year-old female patient, the disease presented with the onset of numbness and weakness in the lower limbs, accompanied by pelvic organ dysfunction. The detection of antibodies to GFAP in serum and cerebrospinal fluid, the clinical picture of encephalomyelitis, and an MRI pattern of linear radial perivascular enhancement on T1-weighted images, along with an extensive (extending from TI to TXI) hyperintense lesion on T2-weighted images, led to a diagnosis of autoimmune anti-GFAP astrocytopathy. By the time the diagnosis was confirmed, the patient presented with marked gait disturbance requiring the use of bilateral support, as well as neurogenic bladder dysfunction necessitating intermittent catheterisation. No clinical or radiological progression of the disease was observed during anti-B-cell therapy with rituximab. This case report adds to the existing evidence on the clinical features of anti-GFAP astrocytopathy and demonstrates the importance of timely diagnosis and early initiation of pathogenetic therapy for the disease.
Case Presentation: A 58-year-old man presented with a 2-month history of burning pain in the left lower limb and a 1-month history of ipsilateral hypoesthesia and gait imbalance. Additional symptoms included cervical electric-shock sensations, progressive dysphonia, tinnitus, and psychomotor slowing. Neurological exami...
João Pedro Sá Lins, Rodrigo de Sousa da Silva, Luciano Gonçalves Do Nascimento et al.· ANPAbstract_CBN26· 0 citations
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has emerged as a distinct inflammatory demyelinating disorder of the central nervous system. Although relatively rare, growing recognition of this entity has highlighted important differences from multiple sclerosis and neuromyelitis optica spectru...
Kavya Rajanna, G. Sharma· International Journal of Con...· 0 citations
Case Presentation: A 15-year-old previously healthy male presented with acute paraparesis (grade 4/5), an L5-S1 sensory level, and urinary retention, associated with febrile peaks, emerging three weeks after infectious mononucleosis. Initial cerebrospinal fluid (CSF) analysis revealed marked pleocytosis (68 cells/µL) w...
Luís Guilherme Fernandes Costa Lima Lima, Fernando Coronetti Gomes da Rocha, I. Kirsten et al.· ANPAbstract_CBN26· 0 citations
Case Presentation: A 17-year-old patient with a previous diagnosis of migraine and mood disorder presented with worsening headache in January 2025. A brain magnetic resonance imaging (MRI) performed at that time showed no significant abnormalities. Trigger-point injections were performed and treatment with fremanezumab...
Eduarda Heringer Bernis, Rafaela Gatti Lopes, Louise Albeny Gonçalves Paris et al.· ANPAbstract_CBN26· 0 citations
Importance
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion di...
Eoin P. Flanagan, Brenda L. Banwell, Laura Cacciaguerra et al.· JAMA Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.